Sandoz, Just-Evotec Biologics have announced a collaboration to develop and manufacture multiple biosimilars. In the said agreement, Sandoz will get access to an AI-led technology platform that goes on to deliver completely integrated development of drug substances as well as consistent manufacturing. This will help in supporting Sandoz’s pipeline elevation to 24 biosimilar assets.
Utilising artificial intelligence so as to manufacture biosimilars
Because of the strategic collaboration, both parties happen to be sharing a commitment to use disruptive technologies with low operational costs in order to deliver biosimilars at a scale of high quality for patients across the world, as per Richard Saynor, the CEO of Sandoz.
By way of intensifying as well as shrinking the footprint of their manufacturing facility with the help of these technologies, the cost of production can be lowered, opined Radal Bass, the executive vice president of process design and biotherapeutic operations at Just-Evotec Biologics.
Consistent manufacturing of biologics
Within this collaboration, Sandoz happens to have the option to make use of Evotec Biologics’ advanced and consistent manufacturing process.
The state-of-the-art manufacturing and drug development technology goes on to deliver elevated quality as well as productivity when it comes to the production of biologics.
As per Richard Saynor, the agreement goes on to offer multiple capabilities to help in the strategic expansion of the pipeline by way of novel assets and to begin the transitioning immediately of the biosimilar pipeline being used earlier, thereby making sure of continuity when it comes to development as well as manufacturing while the planned separation from Novartis is finalised by Sandoz.
Notably, the development of biosimilars is expected to ramp up in the next 12–18 months.